Helen S. Kim, MBA

Helen S. Kim is Senior Managing Director of Vida Ventures. Ms. Kim has over 30 years of experience in leadership roles in biotechnology. Most recently, Ms. Kim was a Partner at The Column Group. Prior, Ms. Kim served as Executive Vice President of Corporate Development at Kite Pharma, Inc. where she led all business and corporate development initiatives successfully selling Kite Pharma to Gilead in 2017.

Previously, Ms. Kim served as Strategic Advisor of NGM Biopharmaceuticals, Inc. from January 2012 through November 2014. Ms. Kim served as the Chief Business Officer at NGM Biopharmaceuticals, Inc. from August 2009 to January 2012. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences where she restructured and repositioned the company prior to successfully selling the company to Bristol-Myers Squibb. Ms. Kim has held various executive and leadership positions at Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc., and Chiron Corporation. From August 2003 to November 2007, Ms. Kim served as Chief Program Officer for the Gordon and Betty Moore Foundation. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and an MBA from the University of Chicago.

Ms. Kim serves on the Board of Directors for Prothena (NASDAQ:PRTA), ReCode Therapeutics, Aktis Oncology, Protego Biopharma, InduPro and IconOVir Bio.